Guidelines for the management of Crohn's disease. Recommendations of the Working Group of the Polish National Consultant in Gastroenterology and the Polish Society of Gastroenterology;Wytyczne Grupy Roboczej Konsultanta Krajowego w dziedzinie Gastroenterologii i Polskiego Towarzystwa Gastroenterologii dotycza̧ce postȩpowania z pacjentem z choroba̧ Leśniowskiego-Crohna

Przeglad Gastroenterologiczny

Volumn 7, Issue 6, 2012, Pages 317-338

  Łodyga, Michał ^a   Eder, Piotr ^b   Bartnik, Witold ^c   Gonciarz, MacIej ^d   Kłopocka, Maria ^e   Linke, Krzysztof ^b   Małecka Panas, Ewa ^f   Radwan, Piotr ^g   Reguła, Jarosław ^c   Rydzewska, Grazyna ^a  

^a Klinika Chorób Wewn trznych I Gastroenterologii Centralnego Szpitala Klinicznego   (Poland)

^b Uniwersytetu Medycznego   (Poland)

^c MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^d Wojewódzkiego Szpitala Specjalistycznego Im Św Barbary ^*  (Poland)

^e NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^f MEDICAL UNIVERSITY OF LODZ   (Poland)

^g Katedra i Klinika Gastroenterologii   (Poland)

Author keywords

Anti TNF; Crohn's disease; Endoscopy; Thiopurines

Indexed keywords

ARTICLE; CROHN DISEASE; DIAGNOSTIC PROCEDURE; MEDICAL SOCIETY; POLAND; PRACTICE GUIDELINE; SCORING SYSTEM; TREATMENT PLANNING;

EID: 84874594933     PISSN: 18955770     EISSN: 18974317     Source Type: Journal    
DOI: 10.5114/pg.2012.33040     Document Type: Article

References (156)

1. Loftus Jr EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004; 126: 1504-17. (Pubitemid 38649869)
2. Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohn's Colitis 2010; 4: 63-101.
3. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. Gastroenterology 1976; 70: 439-44.
4. Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology 2004; 126: 1518-32. (Pubitemid 38649870)
5. Coremans G, Rutgeerts P, Geboes K, et al. The value of ileoscopy with biopsy in the diagnosis of intestinal Crohn's disease. Gastrointest Endosc 1984; 30: 167-72. (Pubitemid 14119871)
6. Geboes K, Ectors N, D'Haens G, Rutgeerts P. Is ileoscopy with biopsy worthwhile in patients presenting with symptoms of inflammatory bowel disease? Am J Gastroenterol 1998; 93: 201-6. (Pubitemid 29063967)
7. Cherian S, Singh P. Is routine ileoscopy useful? An observational study of procedure times, diagnostic yield, and learning curve. Am J Gastroenterol 2004; 99: 2324-9. (Pubitemid 40039360)
8. Allez M, Lemann M, Bonnet J, et al. Long term outcome of patients with active Crohn's disease ECCO Consensus on CD: definitions and diagnosis 23 exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002; 97: 947-53. (Pubitemid 34408253)
9. Horsthuis K, Bipat S, Bennink RJ, Stoker J. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: metaanalysis of prospective studies. Radiology 2008; 247: 64-79.
10. Schmidt S, Lepori D, Meuwly JY, et al. Prospective comparison of MR enteroclysis with multidetector spiral-CT enteroclysis: interobserver agreement and sensitivity by means of "sign-bysign" correlation. Eur Radiol 2003; 13: 1303-11. (Pubitemid 36790632)
11. Fraquelli M, Colli A, Casazza G, et al. Role of US in detection of Crohn disease: meta-analysis. Radiology 2005; 236: 95-101. (Pubitemid 40853300)
12. Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem 2006; 52: 171-81. (Pubitemid 43185477)
13. Reese GE, Constantinides VA, Simillis C, et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol 2006; 101: 2410-22. (Pubitemid 44477569)
14. Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea- predominant functional bowel disorders. Eur J Gastroenterol Hepatol 2002; 14: 409-12. (Pubitemid 34439041)
15. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 661-5. (Pubitemid 39276479)
16. Sachar DB, Luppescu NE, Bodian C, et al. Erythrocyte sedimentation as a measure of Crohn's disease activity: opposite trends in ileitis versus colitis. J Clin Gastroenterol 1990; 12: 643-6.
17. D'Inca R, Dal PE, Di LV, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007; 22: 429-37. (Pubitemid 46336248)
18. Gaya DR, Lyon TD, Duncan A, et al. Faecal calprotectin in the assessment of Crohn's disease activity. QJM 2005; 98: 435-41. (Pubitemid 40796815)
19. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000; 47: 506-13.
20. Mylonaki M, Langmead L, Pantes A, et al. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol 2004; 16: 775-8. (Pubitemid 39062569)
21. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-50. (Pubitemid 34784976)
22. Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010; 139: 1147-55.
23. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology 2006; 130: 650-6. (Pubitemid 43374514)
24. Seksik P, Loftus EV, Beaugerie L, et al. Validation of predictors of 5-year disabling CD in a population-based cohort from Olmsted County, Minnesota 1983-1996. Gastroenterology 2007; 132: A-17.
25. Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008; 43: 948-54.
26. Johnson GJ, Cosnes J, Mansfield JC. Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment Pharmacol Ther 2003; 15: 401-8.
27. Cosnes J, Carbonnel F, Beaugerie L, et al. Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology 1996; 110: 424-31. (Pubitemid 26043875)
28. Breuer-Katschinski BD, Hollander N, Goebell H. Effect of cigarette smoking on the course of Crohn's disease. Eur J Gastroenterol Hepatol 1996; 8: 225-8.
29. Otley A, Steinhart AH. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2005; 4: CD000296.
30. Campieri M, Fergusonj A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997; 41: 209-14. (Pubitemid 27395924)
31. Summers RW, Switz DM, Sessions JT, et al. National cooperative Crohn's disease study group: results of drug treatment. Gastroenterology 1979; 77: 847-69. (Pubitemid 9242048)
32. Malchow H, Ewe K, Brandes JW, et al. European co-operative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249-66. (Pubitemid 14218578)
33. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000; 2: CD000545.
34. Goldenberg BA, Rawsthorne P, Bernstein CN. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol 2004; 99: 1744-8. (Pubitemid 39237503)
35. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate in the treatment of Crohn's disease. N Engl J Med 1995; 332: 292-7.
36. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease (Cochrane Review). Cochrane Database Syst Rev 2003; 1: CD003459.
37. Targan SR, Feagan BG, Fedorak RN, et al. International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007; 132: 1672-83.
38. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000; 342: 1627-32. (Pubitemid 30341531)
39. Kurnik D, Loebstein R, Fishbein E, et al. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther 2003; 18: 57-63. (Pubitemid 36897981)
40. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
41. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500.
42. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human antitumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-33.
43. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-38. (Pubitemid 351650483)
44. Rutgeerts P, D'Haens G, Van Assche G, et al. Adalimumab induces and maintains mucosal healing in patients with moderate to severe Crohn's disease. First results of the EXTEND trial. Gastroenterology 2009; 136: A116 Abstract.
45. Rutgeerts P, Van Assche G, Vermeire S. Optimising anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593-610. (Pubitemid 38649876)
46. Colombel JF, Loftus Jr EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31. (Pubitemid 38040720)
47. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004; 53: 849-53. (Pubitemid 38662135)
48. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-30.
49. Fidder H, Schnitzler F, Ferrante M, et al. Long term safety of infliximab for the treatment of inflammatory bowel disease: a single center cohort study. Gut 2009; 58: 501-8.
50. Colombel JF, Rutgeerts P, Reinisch W, et al. SONIC: a randomized, double blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naïve to immunomodulators and biologic therapy. Gut 2008; 57 Suppl II: A1.
51. Rutgeerts P, Vermeire S, Van Assche G. Predicting the response to infliximab from trough serum levels. Gut 2010; 59: 7-8.
52. Feagan BG. Editorial: 5-ASA therapy for active Crohn's disease: old friends, old data and a new conclusion. Clin Gastroenterol Hepatol 2004; 2: 376-8. (Pubitemid 38561233)
53. Thomsen OO, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn's disease. N Engl J Med 1998; 339: 370-4. (Pubitemid 28363799)
54. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo- controlled trias. Clin Gastroenterol Hepatol 2004; 2: 379-88. (Pubitemid 38561234)
55. Edsbäcker S, Jonsson S, Lindberg C, et al. Metabolic pathways of the topical glucocorticoid budesonide in man. Drug Metab Dispos 1983; 11: 590-6. (Pubitemid 14200950)
56. Tromm A, Bunganic I, Tomsova E, et al. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. Gastroenterology 2011; 140: 425-34.
57. Radwan P. Leczenie farmakologiczne choroby Leśniowskiego- -Crohna. W: Choroba Leśniowskiego-Crohna - 100 lat diagnostyki i terapii. Rydzewska G, Małecka-Panas E (red.). Termedia Wydawnictwa Medyczne, Poznań 2008; 113-30.
58. Seow CH, Benchimol EI, Griffiths AM, et al. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008; 3: CD000296.
59. Benchimol EI, Seow CH, Steinhart AH, et al. Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008; 2: CD006792.
60. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of bu - de sonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331: 842-5. (Pubitemid 24289711)
61. Ho GT, Chiam P, Drummond R, et al. The efficacy of cortico ste - roid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006; 24: 319-30. (Pubitemid 43972900)
62. D'Haens G, Panaccione R, Gassull M, et al. The London Position Statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2010; 106: 199-212.
63. D'Haens G, Baert F, van Assche G, et al. Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosupression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-7. (Pubitemid 351284485)
64. Bossani M, Ardizzone S, Porro GB. Biologic targeting in the treatment of inflammatory bowel diseases. Biologics: Targets and Therapy 2009; 3: 77-97.
65. Weston LA, Roberts PL, Schoetz Jr DJ, et al. Ileocolonic resection for acute presentation of Crohn's disease of the ileum. Dis Colon Rectum 1996; 39: 841-6. (Pubitemid 26332458)
66. Kim NK, Senagore AJ, Luchtefeld MA, et al. Long-term outcome after ileocecal resection for Crohn's disease. Am Surg 1997; 63: 627-33. (Pubitemid 27268587)
67. Graadal O, Nygaard K. Crohn disease. Long-term effects of surgical treatment. Tidsskr Nor Laegeforen 1994; 114: 1603-5.
68. Malchow H, Ewe K, Brandes JW, et al. European co-operative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249-66. (Pubitemid 14218578)
69. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Eng J Med 2010; 362: 1383-95.
70. Panaccione R. Optimal use of biologics in the management of Crohn's disease. Therap Adv Gastroenterol 2010; 3: 179-89.
71. Zachos M, Tondeur M, Griffiths AM. Enteral nutrition therapy for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2007; 1: CD000542.
72. Hanauer SB. Crohn's disease: step up or top down therapy. Best Pract Rec Clin Gastroenterol 2003; 17: 131-7.
73. Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scan J Gastroenterol 2008; 43: 948-54.
74. Tromm A, Tromm CD, Huppe D, Schwegler U, et al. Evaluation of different laboratory tests and activity indices reflecting the inflammatory activity of Crohn's disease. Scand J Gastroenterol 1992; 27: 774-8.
75. Turner D, Griffiths AM. Esophageal, gastric, and duodenal manifestations of IBD and the role of upper endoscopy in IBD diagnosis. Curr Gastroenterol Rep 2007; 9: 475-8. (Pubitemid 351795705)
76. Tremaine WJ. Gastroduodenal Crohn's disease: medical management. Inflamm Bowel Dis 2003; 9: 127-8. (Pubitemid 36367322)
77. Kwan LY, Conklin JL, Papadakis KA. Esophageal Crohn's disease treated successfully with adalimumab. Inflamm Bowel Dis 2007; 13: 639-40. (Pubitemid 46799648)
78. Sandborn WJ, Fazio VVW, Feagan BG, et al. AGA technical review on perianal Crohn's disease. Gastroenterology 2003; 125: 1508-30. (Pubitemid 37409772)
79. Schwartz DA, Loftus EV, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002; 122: 875-80. (Pubitemid 34267269)
80. Solomon MJ, McLeod RS, O'Connor BI, et al. Combination ciprofloxacin and metronidazole in severe perianal Crohn's disease. Can J Gastroenterol 1993; 7: 571-3.
81. Thia KT, Mahadevan U, Feagan BG, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebocontrolled pilot study. Inflamm Bowel Dis 2009; 15: 17-24.
82. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med 1995; 122: 132-42.
83. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-85. (Pubitemid 38252535)
84. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405. (Pubitemid 29205403)
85. Hanauer S, Lukáš M, MacIntosh D, et al. A randomized, double-blind, placebo-controlled trial of the human anti-TNF - a monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease. Gastroenterology 2006; 130: 323-33.
86. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab. Ann Intern Med 2007; 146: 829-38. (Pubitemid 351650483)
87. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65. (Pubitemid 46108762)
88. Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009; 58: 940-8.
89. Gaertner WB, Decanini A, Mellgren A, et al. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas? Dis Colon Rectum 2007; 50: 1754-60.
90. Hyder SA, et al. Fisulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum 2006; 49: 1837-41. (Pubitemid 44853440)
91. Graadal O, Nygaard K. Crohn disease. Long-term effects of surgical treatment. Tidsskr Nor Laegeforen 1994; 114: 1603-5.
92. Nordgren SR, Fasth SB, Oresland TO, Hulten LA. Long-term follow- up in Crohn's disease. Mortality, morbidity, and functional status. Scand J Gastroenterol 1994; 29: 1122-8. (Pubitemid 24374804)
93. Weston LA, Roberts PL, Schoetz Jr DJ, et al. Ileocolic resection for acute presentation of Crohn's disease of the ileum. Dis Colon Rectum 1996; 39: 841-6. (Pubitemid 26332458)
94. Kim NK, Senagore AJ, Luchtefeld MA, et al. Long-term outcome after ileocecal resection for Crohn's disease. Am Surg 1997; 63: 627-33. (Pubitemid 27268587)
95. Tilney HS, Constantinides VA, Heriot AG, et al. Comparison of laparoscopic and open ileocecal resection for Crohn's disease: a meta-analysis. Surg Endosc 2006; 20: 1036-44. (Pubitemid 44078436)
96. Lesperance K, Martin MJ, Lehmann R, et al. National trends and outcomes for the surgical therapy of ileocolonic Crohn's disease: a population-based analysis of laparoscopic vs. open approaches. J Gastrointest Surg 2009.
97. Milsom JW, Hammerhofer KA, Bohm B, et al. Prospective, randomized trial comparing laparoscopic vs. conventional surgery for refractory ileocolic Crohn's disease. Dis Colon Rectum 2001; 44: 1-8.
98. Hassan C, Zullo A, De FV, et al. Systematic review: endoscopic dilatation in Crohn's disease. Aliment Pharmacol Ther 2007; 26: 1457-64. (Pubitemid 350178804)
99. Breysem Y, Janssens JF, Coremans G, et al. Endoscopic balloon dilation of colonic and ileo-colonic Crohn's strictures: longterm results. Gastrointest Endosc 1992; 38: 142-7.
100. Thomas-Gibson S, Brooker JC, Hayward CM, et al. Colonoscopic balloon dilation of Crohn's strictures: a review of longterm outcomes. Eur J Gastroenterol Hepatol 2003; 15: 485-8. (Pubitemid 36571039)
101. Yamamoto T, Fazio VW, Tekkis PP. Safety and efficacy of strictureplasty for Crohn's disease: a systematic review and metaanalysis. Dis Colon Rectum 2007; 50: 1968-86. (Pubitemid 350077088)
102. Fearnhead NS, Chowdhury R, Box B, et al. Long-term followup of strictureplasty for Crohn's disease. Br J Surg 2006; 93: 475-82.
103. Reese GE, Purkayastha S, Tilney HS, et al. Strictureplasty vs resection in small bowel Crohn's disease: an evaluation of short-term outcomes and recurrence. Colorectal Dis 2007; 9: 686-94. (Pubitemid 47422966)
104. Aberra FN, Lewis JD, Hass D, et al. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 2003; 125: 320-6.
105. Tay GS, Binion DG, Eastwood D, Otterson MF. Multivariate analysis suggests improved perioperative outcome in Crohn's disease patients receiving immunomodulator therapy after segmental resection and/or strictureplasty. Surgery 2003; 34: 565-72.
106. Myrelid P, Andersson P, Sjödahl R, Olaison G. Immunosuppression for Crohn's disease is associated with increased frequency of anastomotic complications. Colorectal Dis 2004; 6: 26.
107. Colombel JF, Loftus Jr EV, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004; 99: 878-83. (Pubitemid 39090217)
108. Appau KA, Fazio VW, Shen B, et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg 2008; 12: 1738-44.
109. Mahadevan U, Loftus Jr EV, Tremaine WJ, et al. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis 2002; 8: 311-6.
110. Reese GE, Nanidis T, Borysiewicz C, et al. The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies. Int J Colorectal Dis 2008; 23: 1213-21.
111. Vermeire S, Carbonnel F, Coulie PG, et al. Management of inflammatory bowel disease in pregnancy. J Crohns Colitis 2012; 6: 811-23.
112. Andrews JM, Mountifield RE, Van Lengenberg DR, et al. Unprompted issues in inflammatory bowel disease: opportunities to optimize care. Intern Med J 2010; 40: 173-82.
113. Mountfield R, Bampton P, Prosser R, et al. Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions. Inflamm Bowel Dis 2009; 15: 720-5.
114. Gorgun E, Remzi FH, Goldberg JM, et al. Fertility is reduced after restorative proctocolectomy with ileal pouch anastomosis: a study of 300 patients. Surgery 2004; 136: 795-803. (Pubitemid 39311305)
115. Toovey S, Hudson S, Hendry WF, et al. Sulphasalazine and male fertility: reversibility and possible mechanisms. Gut 1981; 22: 445-51. (Pubitemid 11053277)
116. Toth A. Reversible toxic effect of salicylazosulfapyridine on semen quality. Fertil Steril 1979; 31: 538-40. (Pubitemid 9150062)
117. Moskovitz DN, Bodian C, Chapman ML, et al. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 2004; 99: 656-61. (Pubitemid 38607969)
118. Hernandez-Diaz S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defect. N Engl J Med 2000; 343: 1608-14. (Pubitemid 32162984)
119. Rahimi R, Nikfar S, Rezaie A, et al. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol 2008; 25: 271-5.
120. Hernandez-Diaz S, Mitchell AA, Kelley KE, et al. Medications as a potential source of exposure to phtalates in the U.S. population. Environ Health Perspect 2009; 117: 185-9.
121. Czeizel AE, Rockenbauer M. A population based case-control teratologic study of oral metronidazol treatment during pregnancy. Br J Obstet Gynaecol 1998; 105: 322-7. (Pubitemid 28123583)
122. Burtin P, Taddio A, Ariburnu O, et al. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol 1995; 172: 525-9.
123. Loebstein R, Addis A, Ho E, et al. Pregnancy outcome follow - ing gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemoter 1998; 42: 1336-9. (Pubitemid 28257627)
124. Park-Wylie JD. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62: 385-92.
125. Mahadevan U, Cucchiara S, Hyams JS, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol 2011; 106: 214-23.
126. Ostensen M, Forger F. Management of RA medications in pregnant patients. Nat Rev Rheumatol 2009; 5: 382-90.
127. Cleary BJ, Kallen B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol 2009; 85: 647-54.
128. Rajapakse RO, Korelitz BI, Zlatanic J, et al. Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol 2000; 95: 684-8. (Pubitemid 30123902)
129. Langagergaard V, Pedersen L, Gislum M, et al. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: a Danish nationwide cohort study. Aliment Pharmacol Ther 2007; 25: 73-81. (Pubitemid 44902866)
130. Coelho J, Beaugerie L, Colombel JF, et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 2011; 60: 198-203.
131. Carter JD, Ladhani A, Ricca LR, et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 2009; 36: 635-41.
132. Mahadevan U, Kane S. Use of infliximab in pregnancy. Am J Gastroenterol 2010; 105: 219-20.
133. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidencebased consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3: 47-91.
134. Cheent K, Nolan J, Shariq S, et al. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 2010; 4: 603-5.
135. Rahier JF, Moutschen M, Van Gompel A, et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford) 2010; 49: 1815-27.
136. Ostensen M, Hartmann H, Salvesen K. Low dose weekly methotrexate in early pregnancy. A case series and review of the literature. J Rheumatol 2000; 27: 1872-5. (Pubitemid 30670480)
137. Ostensen M, Motta M. Therapy insight: the use of antirheumatic drugs during nursing. Nat Clin Pract Rheumatol 2007; 3: 400-6. (Pubitemid 47034541)
138. Christensen LA, Dahlerup JF, Nielsen MJ, et al. Azathioprine treatment during lactation. Aliment Pharmacol Ther 2008; 28: 1209-13.
139. Brandt LJ, Estabrook SG, Reinus JF. Results of a survey to evaluate wheter vaginal delivery and episiotomy lead to perianal involvement in women with Crohn's disease. Am J Gastroenterol 1995; 90: 1918-22.
140. Reinshagen M. Osteoporosis in inflammatory bowel disease. J Crohns Colitis 2008; 2: 202-7.
141. Trost LB, McDonnel JK. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J 2005; 81: 580-5. (Pubitemid 41297914)
142. Requena L, Sanchez Yus E. Erythema nodosum. Semin Cutan Med Surg 2007; 26: 114-25. (Pubitemid 46829963)
143. Freeman HJ. Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn's disease. Can J Gastroenterol 2005; 19: 603-6. (Pubitemid 41723284)
144. Clayton TH, Walker BP, Stables GI. Treatment of chronic erythema nodosum with infliximab. Clin Exp Dermatol 2006; 31: 823-4. (Pubitemid 44563409)
145. Torzecka JD, Kondras K, Dziankowska-Bartkowiak B, et al. Piodermia zgorzelinowa - interdyscyplinarny problem diagnostyczny. Pol Merk Lek 2008; 24: 34-7.
146. Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ 2006; 333: 181-4. (Pubitemid 44406745)
147. Brooklyn TN, Dunnill MGS, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomized, doubleblind, placebo controlled trial. Gut 2006; 55: 505-9.
148. Poritz LS, Lebo MA, Bobb AD, et al. Management of peristomal pyoderma gangrenosum. J Am Coll Surg 2008; 206: 311-5.
149. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998; 42: 387-91. (Pubitemid 28197029)
150. Fornaciari G, Salvarani C, Beltrami M, et al. Musculoskeletal manifestations in inflammatory bowel disease. Can J Gastroenterol 2001; 15: 399-403. (Pubitemid 32684667)
151. Bonner GF, Fakhri A, Vennamanen SR. A long-term cohort study of non-steroidal antiinflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 751-7. (Pubitemid 39545220)
152. Dougados M, Van der Linden S, Leirisalo-Repo M. Sulfasalazine in the treatment of spondyloarthropathy. A randomised multicenter, double-blind placebo controlled study. Arthritis Rheum 1995; 38: 618-27.
153. De Vlam K, Mielants H, Cuvelier C, et al. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol 2000; 27: 2860-5.
154. Gorman J, Sack K, Davis J. Treatment of active ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346: 1349-56. (Pubitemid 34754607)
155. Stawczyk-Eder K, Eder P, Łykowska-Szuber L, et al. Strategia szczepień w nieswoistych zapaleniach jelit. Gastroenterol Prakt 2010; 3: 64-8.
156. Tourner M, Loftus Jr EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-36. (Pubitemid 351451967)